Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)Depreciation ExpenseEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetShares Repurchased
Ratios

Ani Pharmaceuticals (ANIP) Receivables - Other (2018 - 2022)

Ani Pharmaceuticals (ANIP) has disclosed Receivables - Other for 5 consecutive years, with $5.0 million as the latest value for Q4 2022.

  • Quarterly Receivables - Other changed N/A to $5.0 million in Q4 2022 from the year-ago period, while the trailing twelve-month figure was $5.0 million through Dec 2022, changed N/A year-over-year, with the annual reading at $5.0 million for FY2022, N/A changed from the prior year.
  • Receivables - Other hit $5.0 million in Q4 2022 for Ani Pharmaceuticals, up from $100000.0 in the prior quarter.
  • In the past five years, Receivables - Other ranged from a high of $5.0 million in Q4 2022 to a low of $14000.0 in Q3 2018.
  • Historically, Receivables - Other has averaged $581400.0 across 4 years, with a median of $100000.0 in 2018.
  • Biggest YoY gain for Receivables - Other was 614.29% in 2019; the steepest drop was 0.0% in 2019.
  • Year by year, Receivables - Other stood at $100000.0 in 2018, then changed by 0.0% to $100000.0 in 2019, then changed by 0.0% to $100000.0 in 2020, then skyrocketed by 4900.0% to $5.0 million in 2022.
  • Business Quant data shows Receivables - Other for ANIP at $5.0 million in Q4 2022, $100000.0 in Q3 2020, and $100000.0 in Q2 2020.